Summary: Manipulation of the host's immune system in treatment of disease. It includes both active and passive immunization as well as immunosuppressive therapy to prevent graft rejection.

Top Publications

  1. pmc Immuno-oncology biomarkers 2010 and beyond: perspectives from the iSBTc/SITC biomarker task force
    Lisa H Butterfield
    Departments of Medicine, Surgery and Immunology, University of Pittsburgh, Pittsburgh, PA, USA
    J Transl Med 8:130. 2010
  2. ncbi Sipuleucel-T immunotherapy for castration-resistant prostate cancer
    Philip W Kantoff
    Dana Farber Cancer Institute, Harvard Medical School, Boston, MA 02115, USA
    N Engl J Med 363:411-22. 2010
  3. ncbi Cancer immunoediting: integrating immunity's roles in cancer suppression and promotion
    Robert D Schreiber
    Department of Pathology and Immunology, Washington University School of Medicine, St Louis, MO 63110, USA
    Science 331:1565-70. 2011
  4. ncbi The blockade of immune checkpoints in cancer immunotherapy
    Drew M Pardoll
    Johns Hopkins University School of Medicine, Sidney Kimmel Comprehensive Cancer Center, CRB1 Room 444, 1650 Orleans Street, Baltimore, Maryland 21287, USA
    Nat Rev Cancer 12:252-64. 2012
  5. pmc Chimeric antigen receptor-modified T cells in chronic lymphoid leukemia
    David L Porter
    Abramson Cancer Center, and Department of Medicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia, USA
    N Engl J Med 365:725-33. 2011
  6. pmc Combining immunotherapy and targeted therapies in cancer treatment
    Matthew Vanneman
    Department of Medical Oncology and Cancer Vaccine Center, Dana Farber Cancer Institute and Department of Medicine, Brigham and Women s Hospital and Harvard Medical School, Boston, Massachusetts 02215, USA
    Nat Rev Cancer 12:237-51. 2012
  7. pmc Cancer immunotherapy comes of age
    Ira Mellman
    Genentech, 1 DNA Way, South San Francisco, California 94080, USA
    Nature 480:480-9. 2011
  8. pmc Tumor regression in patients with metastatic synovial cell sarcoma and melanoma using genetically engineered lymphocytes reactive with NY-ESO-1
    Paul F Robbins
    National Institutes of Health, National Cancer Institute, Surgery Branch, Bethesda, MD 20892 1201, USA
    J Clin Oncol 29:917-24. 2011
  9. ncbi Guidelines for the evaluation of immune therapy activity in solid tumors: immune-related response criteria
    Jedd D Wolchok
    Ludwig Center for Cancer Immunotherapy and Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
    Clin Cancer Res 15:7412-20. 2009
  10. ncbi Regulatory T cells, tumour immunity and immunotherapy
    Weiping Zou
    Department of Surgery, University of Michigan, 1500 East Medical Center Drive, Ann Arbor, Michigan 48109 0346, USA
    Nat Rev Immunol 6:295-307. 2006

Detail Information

Publications303 found, 100 shown here

  1. pmc Immuno-oncology biomarkers 2010 and beyond: perspectives from the iSBTc/SITC biomarker task force
    Lisa H Butterfield
    Departments of Medicine, Surgery and Immunology, University of Pittsburgh, Pittsburgh, PA, USA
    J Transl Med 8:130. 2010
    The International Society for Biological Therapy of Cancer (iSBTc, recently renamed the Society for Immunotherapy of Cancer, SITC) hosted a one-day symposium at the National Institutes of Health on September 30, 2010 to address ..
  2. ncbi Sipuleucel-T immunotherapy for castration-resistant prostate cancer
    Philip W Kantoff
    Dana Farber Cancer Institute, Harvard Medical School, Boston, MA 02115, USA
    N Engl J Med 363:411-22. 2010
    Sipuleucel-T, an autologous active cellular immunotherapy, has shown evidence of efficacy in reducing the risk of death among men with metastatic castration-resistant prostate cancer.
  3. ncbi Cancer immunoediting: integrating immunity's roles in cancer suppression and promotion
    Robert D Schreiber
    Department of Pathology and Immunology, Washington University School of Medicine, St Louis, MO 63110, USA
    Science 331:1565-70. 2011
    ..Here, we discuss a unifying conceptual framework called "cancer immunoediting," which integrates the immune system's dual host-protective and tumor-promoting roles...
  4. ncbi The blockade of immune checkpoints in cancer immunotherapy
    Drew M Pardoll
    Johns Hopkins University School of Medicine, Sidney Kimmel Comprehensive Cancer Center, CRB1 Room 444, 1650 Orleans Street, Baltimore, Maryland 21287, USA
    Nat Rev Cancer 12:252-64. 2012
  5. pmc Chimeric antigen receptor-modified T cells in chronic lymphoid leukemia
    David L Porter
    Abramson Cancer Center, and Department of Medicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia, USA
    N Engl J Med 365:725-33. 2011
    ..Remission was ongoing 10 months after treatment. Hypogammaglobulinemia was an expected chronic toxic effect...
  6. pmc Combining immunotherapy and targeted therapies in cancer treatment
    Matthew Vanneman
    Department of Medical Oncology and Cancer Vaccine Center, Dana Farber Cancer Institute and Department of Medicine, Brigham and Women s Hospital and Harvard Medical School, Boston, Massachusetts 02215, USA
    Nat Rev Cancer 12:237-51. 2012
    ..of cancer pathogenesis has given rise to new treatment options, including targeted agents and cancer immunotherapy. Targeted approaches aim to inhibit molecular pathways that are crucial for tumour growth and maintenance; ..
  7. pmc Cancer immunotherapy comes of age
    Ira Mellman
    Genentech, 1 DNA Way, South San Francisco, California 94080, USA
    Nature 480:480-9. 2011
    ..immunosuppression regulate antitumour immune responses together with the advent of targeted therapies, these successes suggest that active immunotherapy represents a path to obtain a durable and long-lasting response in cancer patients.
  8. pmc Tumor regression in patients with metastatic synovial cell sarcoma and melanoma using genetically engineered lymphocytes reactive with NY-ESO-1
    Paul F Robbins
    National Institutes of Health, National Cancer Institute, Surgery Branch, Bethesda, MD 20892 1201, USA
    J Clin Oncol 29:917-24. 2011
    Adoptive immunotherapy using tumor-infiltrating lymphocytes represents an effective cancer treatment for patients with metastatic melanoma...
  9. ncbi Guidelines for the evaluation of immune therapy activity in solid tumors: immune-related response criteria
    Jedd D Wolchok
    Ludwig Center for Cancer Immunotherapy and Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
    Clin Cancer Res 15:7412-20. 2009
    ..Novel criteria for the evaluation of antitumor responses with immunotherapeutic agents are required...
  10. ncbi Regulatory T cells, tumour immunity and immunotherapy
    Weiping Zou
    Department of Surgery, University of Michigan, 1500 East Medical Center Drive, Ann Arbor, Michigan 48109 0346, USA
    Nat Rev Immunol 6:295-307. 2006 dampen T-cell immunity to tumour-associated antigens and to be the main obstacle tempering successful immunotherapy and active vaccination...
  11. pmc Normalization of obesity-associated insulin resistance through immunotherapy
    Shawn Winer
    Department of Pediatrics and Immunology, Research Institute, The Hospital for Sick Children, University of Toronto, Toronto, Ontario, Canada
    Nat Med 15:921-9. 2009
    ..The eventual failure of this control, with expanding adiposity and pathogenic VAT T cells, can successfully be reversed by immunotherapy.
  12. pmc Cancer immunotherapy via dendritic cells
    Karolina Palucka
    Baylor Institute for Immunology Research, 3434 Live Oak Avenue, Dallas, Texas 75204, USA
    Nat Rev Cancer 12:265-77. 2012
    Cancer immunotherapy attempts to harness the power and specificity of the immune system to treat tumours. The molecular identification of human cancer-specific antigens has allowed the development of antigen-specific immunotherapy...
  13. pmc Interleukin-2 at the crossroads of effector responses, tolerance, and immunotherapy
    Wei Liao
    Laboratory of Molecular Immunology and Immunology Center, National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, MD 20892 1674, USA
    Immunity 38:13-25. 2013
  14. ncbi Immunosuppressive networks in the tumour environment and their therapeutic relevance
    Weiping Zou
    Tulane University Health Sciences Center, Section of Hematology and Medical Oncology, 1430 Tulane Avenue, New Orleans, Louisiana 70112 2699, USA
    Nat Rev Cancer 5:263-74. 2005
    ..Why then has tumour immunotherapy resulted in a generally poor clinical efficiency? The reason might lie in the increasingly documented fact ..
  15. pmc Phenotype, distribution, generation, and functional and clinical relevance of Th17 cells in the human tumor environments
    Ilona Kryczek
    Department of Surgery, University of Michigan, Ann Arbor, MI 48109 0669, USA
    Blood 114:1141-9. 2009
    ..This study thus provides scientific and clinical rationale for developing novel immune-boosting strategies based on promoting the Th17 cell population in cancer patients...
  16. pmc Monoclonal antibodies: versatile platforms for cancer immunotherapy
    Louis M Weiner
    Lombardi Comprehensive Cancer Center, Georgetown University Medical Center, Washington, DC 20057, USA
    Nat Rev Immunol 10:317-27. 2010
    ..These immunomodulatory properties can form the basis for new cancer treatment strategies...
  17. pmc Blockade of CTLA-4 on both effector and regulatory T cell compartments contributes to the antitumor activity of anti-CTLA-4 antibodies
    Karl S Peggs
    Howard Hughes Medical Institute, Department of Immunology, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    J Exp Med 206:1717-25. 2009 to evaluate the independent contributions of CTLA-4 blockade of each T cell compartment during cancer immunotherapy in an in vivo model of mouse melanoma...
  18. ncbi Cancer/testis (CT) antigens: potential targets for immunotherapy
    Otavia L Caballero
    Ludwig Institute for Cancer Research, New York Branch at Memorial Sloan Kettering Cancer Center, New York City, USA
    Cancer Sci 100:2014-21. 2009
    ..Cancer vaccine trials based on CT antigens MAGE-A3 and NY-ESO-1 are currently ongoing, and these antigens may also play a role in antigen-specific adoptive T-cell transfer and in the immunomodulation approach of cancer therapy...
  19. pmc Cancer immunotherapy: moving beyond current vaccines
    Steven A Rosenberg
    Surgery Branch of the Center for Cancer Research at the National Cancer Institute, Building 10, Room 2B42, 10 Center Drive, MSC 1502 Bethesda, Maryland 20892 1502, USA
    Nat Med 10:909-15. 2004
    ..6%), and comparable to the results obtained by others. We consider here results in cancer vaccine trials and highlight alternate strategies that mediate cancer regression in preclinical and clinical models...
  20. ncbi Neuroblastoma: developmental biology, cancer genomics and immunotherapy
    Nai Kong V Cheung
    Department of Pediatrics, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA
    Nat Rev Cancer 13:397-411. 2013
    ..In this Review we discuss the key discoveries in the developmental biology, molecular genetics and immunology of neuroblastoma, as well as new translational tools for bringing these promising scientific advances into the clinic...
  21. ncbi Gemcitabine selectively eliminates splenic Gr-1+/CD11b+ myeloid suppressor cells in tumor-bearing animals and enhances antitumor immune activity
    Eiji Suzuki
    Thoracic Oncology Research Laboratory, University of Pennsylvania, Philadelphia, PA 19104, USA
    Clin Cancer Res 11:6713-21. 2005
    ..Elimination of these myeloid suppressor cells may thus significantly improve antitumor responses and enhance effects of cancer immunotherapy, although to date few practical options exist.
  22. ncbi Successful adoptive transfer and in vivo expansion of human haploidentical NK cells in patients with cancer
    Jeffrey S Miller
    Division Medical and Pediatric Hematology Oncology, University of Minnesota Cancer Center, Minneapolis, MN 55455, USA
    Blood 105:3051-7. 2005
    ..These findings suggest that haploidentical NK cells can persist and expand in vivo and may have a role in the treatment of selected malignancies used alone or as an adjunct to HCT...
  23. ncbi Interleukin-12 in anti-tumor immunity and immunotherapy
    Mario P Colombo
    Department of Experimental Oncology, Immunotherapy and Gene Therapy Unit, Istituto Nazionale Tumori, Via G Venezian 1, Milan 20133, Italy
    Cytokine Growth Factor Rev 13:155-68. 2002
    ..The promising data obtained in the pre-clinical models of anti-tumor immunotherapy have raised much hope that IL-12 could be a powerful therapeutic agent against cancer...
  24. pmc Adoptive cell transfer: a clinical path to effective cancer immunotherapy
    Steven A Rosenberg
    Surgery Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, 10 Center Drive, Bethesda, Maryland 20892, USA
    Nat Rev Cancer 8:299-308. 2008
    ..cancer regression in patients, which has recently been demonstrated, has opened possibilities for the extension of ACT immunotherapy to patients with a wide variety of cancer types and is a promising new approach to cancer treatment.
  25. pmc Improved endpoints for cancer immunotherapy trials
    Axel Hoos
    Cancer Immunotherapy Consortium of the Cancer Research Institute, New York, NY, USA
    J Natl Cancer Inst 102:1388-97. 2010
    ..Thus, adequate design and evaluation of some immunotherapy clinical trials require a new development paradigm that includes reconsideration of established endpoints...
  26. ncbi Cancer immunotherapy by dendritic cells
    Cornelis J M Melief
    Department of Immunohematology, Leiden University Medical Center, 2300 RC Leiden, the Netherlands ISA Pharmaceuticals, 3723 MB Bilthoven, The Netherlands
    Immunity 29:372-83. 2008
    ..Here, I discuss the considerations for generating promising therapeutic antitumor vaccines that use DCs...
  27. ncbi Immunotherapy of breast cancer by single delivery with rAAV2-mediated interleukin-15 expression
    Yung luen Yu
    Graduate Institute of Cancer Biology and Center for Molecular Medicine, China Medical University and Hospital, Taichung, Taiwan, ROC
    Int J Oncol 36:365-70. 2010
    ..Furthermore, prominent apoptosis was observed in tumor lesions following injection of rAAV2-hIL15. Taken together, our results suggested that rAAV2-hIL15 appears as a new potential therapeutic tool for breast cancer immunotherapy.
  28. ncbi Effect of immunotherapy with bapineuzumab on cerebrospinal fluid biomarker levels in patients with mild to moderate Alzheimer disease
    Kaj Blennow
    Clinical Neurochemistry Laboratory, Sahlgrenska Academy, University of Gothenburg, Molndal, Sweden
    Arch Neurol 69:1002-10. 2012
    ..Therefore, biomarkers are essential to prove that an anti-β-amyloid (Aβ) drug candidate affects both Aβ metabolism and plaque load as well as downstream pathogenic mechanisms...
  29. pmc Immunotherapy of cancer in 2012
    John M Kirkwood
    Melanoma and Skin Cancer Program, University of Pittsburgh Cancer Institute, Hillman Cancer Center, Pittsburgh, PA 15213, USA
    CA Cancer J Clin 62:309-35. 2012
    The immunotherapy of cancer has made significant strides in the past few years due to improved understanding of the underlying principles of tumor biology and immunology...
  30. ncbi Immunotherapy of cancer with 4-1BB
    Dass S Vinay
    Section of Clinical Immunology, Allergy, and Rheumatology, Department of Medicine, Tulane University Health Sciences Center, New Orleans, LA 70112, USA
    Mol Cancer Ther 11:1062-70. 2012
    ..In this review, we discuss the basis of the therapeutic potential of targeting the 4-1BB-4-1BBL pathway in cancer treatment...
  31. ncbi Safety, tolerability, and antibody response of active Aβ immunotherapy with CAD106 in patients with Alzheimer's disease: randomised, double-blind, placebo-controlled, first-in-human study
    Bengt Winblad
    Karolinska Institutet Alzheimer Disease Research Centre and Clinical Trial Unit, Geriatric Clinic, Karolinska University Hospital, Huddinge, Sweden
    Lancet Neurol 11:597-604. 2012
    b>Immunotherapy targeting the amyloid β (Aβ) peptide is a potential strategy to slow the progression of Alzheimer's disease...
  32. pmc CD28 costimulation improves expansion and persistence of chimeric antigen receptor-modified T cells in lymphoma patients
    Barbara Savoldo
    Center for Cell and Gene Therapy, Baylor College of Medicine, Houston, Texas, USA
    J Clin Invest 121:1822-6. 2011
  33. pmc Arginine regulation by myeloid derived suppressor cells and tolerance in cancer: mechanisms and therapeutic perspectives
    Paulo C Rodriguez
    Department of Genetics, Louisiana State University Health Sciences Center, New Orleans, LA, USA
    Immunol Rev 222:180-91. 2008
    ..T-cell response that can decrease the potential therapeutic benefit of cancer vaccines and other forms of immunotherapy. L-arginine (L-Arg) is a conditionally essential amino acid that is fundamental for the function of T ..
  34. doi Cancer immunology
    Olivera J Finn
    Department of Immunology, University of Pittsburgh School of Medicine, E1044, Biomedical Science Tower, Pittsburgh, PA 15261, USA
    N Engl J Med 358:2704-15. 2008
  35. ncbi Immunological aspects of cancer chemotherapy
    Laurence Zitvogel
    INSERM, U805, Institut Gustave Roussy, 39 rue Camille Desmoulins, F 94805 Villejuif, Paris, France
    Nat Rev Immunol 8:59-73. 2008
    ..Here, we review the immunological aspects of conventional cancer treatments and propose that future successes in the fight against cancer will rely on the development and clinical application of combined chemo- and immunotherapies...
  36. ncbi Magnetic resonance tracking of dendritic cells in melanoma patients for monitoring of cellular therapy
    I Jolanda M de Vries
    Department of Tumor Immunology, Radboud University Nijmegen Medical Center and Nijmegen Center for Molecular Life Sciences, Geert Grooteplein 28, 6500 HB Nijmegen, The Netherlands
    Nat Biotechnol 23:1407-13. 2005
    ..MRI cell tracking using iron oxides appears clinically safe and well suited to monitor cellular therapy in humans...
  37. pmc T(H)17 cells in tumour immunity and immunotherapy
    Weiping Zou
    Department of Surgery, University of Michigan School of Medicine, Ann Arbor, 48109 0669, USA
    Nat Rev Immunol 10:248-56. 2010
    ..Understanding the nature of T(H)17 cell responses in the tumour microenvironment will be important for the design of more efficacious cancer immunotherapies...
  38. ncbi Placebo-controlled phase III trial of immunologic therapy with sipuleucel-T (APC8015) in patients with metastatic, asymptomatic hormone refractory prostate cancer
    Eric J Small
    UCSF Comprehensive Cancer Center, University of California, San Francisco, 1600 Divisadero St, Box 1711, San Francisco, CA 94115, USA
    J Clin Oncol 24:3089-94. 2006
    Sipuleucel-T (APC8015) is an investigational immunotherapy product designed to stimulate T-cell immunity against prostatic acid phosphatase...
  39. pmc Cancer regression and autoimmunity induced by cytotoxic T lymphocyte-associated antigen 4 blockade in patients with metastatic melanoma
    Giao Q Phan
    Surgery Branch, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, USA
    Proc Natl Acad Sci U S A 100:8372-7. 2003
    ..Blockade of CTLA-4 has been shown in animal models to improve the effectiveness of cancer immunotherapy. We thus treated 14 patients with metastatic melanoma by using serial i.v...
  40. pmc Generation of tumor-infiltrating lymphocyte cultures for use in adoptive transfer therapy for melanoma patients
    Mark E Dudley
    Surgery Branch, National Cancer Institute, Department of Transfusion Medicine, Clinical Center, National Institutes of Health, Bethesda, MD 20892 1502, USA
    J Immunother 26:332-42. 2003
    ..These methods were efficient at generating TILs suitable for adoptive transfer therapy...
  41. pmc NKAML: a pilot study to determine the safety and feasibility of haploidentical natural killer cell transplantation in childhood acute myeloid leukemia
    Jeffrey E Rubnitz
    Department of Oncology, St Jude Children s Research Hospital, 262 Danny Thomas Place, Memphis, TN 38105 2794, USA
    J Clin Oncol 28:955-9. 2010
    ..We propose to further investigate the efficacy of KIR-mismatched NK cells in a phase II trial as consolidation therapy to decrease relapse without increasing mortality in children with AML...
  42. pmc Clinical experience and laboratory investigations in patients with anti-NMDAR encephalitis
    Josep Dalmau
    Department of Neurology, University of Pennsylvania School of Medicine, Philadelphia, PA 19104, USA
    Lancet Neurol 10:63-74. 2011
    ..Patients treated with tumour resection and immunotherapy (corticosteroids, intravenous immunoglobulin, or plasma exchange) respond faster to treatment and less ..
  43. ncbi The biology of interleukin-2 and interleukin-15: implications for cancer therapy and vaccine design
    Thomas A Waldmann
    Metabolism Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, Maryland 20892, USA
    Nat Rev Immunol 6:595-601. 2006
    ..As discussed in this Review, the biology of these cytokines will affect the development of novel therapies for malignancy and autoimmune diseases, as well as the design of vaccines against infectious diseases...
  44. pmc Antibodies to Kv1 potassium channel-complex proteins leucine-rich, glioma inactivated 1 protein and contactin-associated protein-2 in limbic encephalitis, Morvan's syndrome and acquired neuromyotonia
    Sarosh R Irani
    Neurosciences Group, Department of Clinical Neurology, University of Oxford, John Radcliffe Hospital, Oxford, UK
    Brain 133:2734-48. 2010
  45. pmc Combining radiotherapy and cancer immunotherapy: a paradigm shift
    Silvia C Formenti
    Department of Radiation Oncology, New York University School of Medicine, 160 E 34th St, New York, NY 10016, USA
    J Natl Cancer Inst 105:256-65. 2013
    ..Recent examples of objective responses achieved by adding radiotherapy to immunotherapy in metastatic cancer patients support this view...
  46. pmc Vascular normalizing doses of antiangiogenic treatment reprogram the immunosuppressive tumor microenvironment and enhance immunotherapy
    Yuhui Huang
    Edwin L Steele Laboratory of Tumor Biology, Department of Radiation Oncology and Vaccine and Immunotherapy Center, Infectious Diseases Medicine, Massachusetts General Hospital and Harvard Medical School, Boston, MA 02114, USA
    Proc Natl Acad Sci U S A 109:17561-6. 2012
    ..Antiangiogenic agents have the potential to modulate the tumor microenvironment and improve immunotherapy, but they often are used at high doses in the clinic to prune tumor vessels and paradoxically may compromise ..
  47. pmc Defining the critical hurdles in cancer immunotherapy
    Bernard A Fox
    Earle A, Chiles Research Institute, Robert W, Franz Research Center, Providence Cancer Center, Providence Portland Medical Center, Portland, OR, USA
    J Transl Med 9:214. 2011
    ..In late 2009 and 2010 the Society for Immunotherapy of Cancer (SITC), convened an "Immunotherapy Summit" with representatives from immunotherapy organizations ..
  48. pmc The anticancer immune response: indispensable for therapeutic success?
    Laurence Zitvogel
    INSERM, U805, Villejuif, France
    J Clin Invest 118:1991-2001. 2008
  49. pmc Intrinsic and extrinsic control of peripheral T-cell tolerance by costimulatory molecules of the CD28/ B7 family
    Helene Bour-Jordan
    UCSF Diabetes Center, University of California at San Francisco, San Francisco, CA 94143 0400, USA
    Immunol Rev 241:180-205. 2011
  50. ncbi Angiogenesis and immunity: a bidirectional link potentially relevant for the monitoring of antiangiogenic therapy and the development of novel therapeutic combination with immunotherapy
    Eric Tartour
    INSERM U970 PARCC, Universite Paris Descartes, 56 rue Leblanc, 75015 Paris, France
    Cancer Metastasis Rev 30:83-95. 2011
    ..In preclinical models, a synergy has been observed between antiangiogenic molecules and immunotherapy which may be explained by an improvement of immune status in tumor-bearing mice after antiangiogenic therapy...
  51. pmc Chemotherapy enhances tumor cell susceptibility to CTL-mediated killing during cancer immunotherapy in mice
    Rupal Ramakrishnan
    H Lee Moffitt Cancer Center and Research Institute, Tampa, Florida 33612, USA
    J Clin Invest 120:1111-24. 2010
    Cancer immunotherapy faces a serious challenge because of low clinical efficacy...
  52. ncbi 'Clinical trials in Alzheimer's disease': immunotherapy approaches
    Julien Delrieu
    Alzheimer s Disease Clinical Research Centre, Gerontopole, Toulouse University Hospital, France INSERM 1027, France
    J Neurochem 120:186-93. 2012
    ..Several types of Aβ peptide immunotherapy for Alzheimer's disease are under investigation, direct immunization with synthetic intact Aβ(42) , active ..
  53. ncbi Cell transfer immunotherapy for metastatic solid cancer--what clinicians need to know
    Steven A Rosenberg
    Surgery Branch, National Cancer Institute, National Institutes of Health, CRC Building 10, Room 3 3940, 10 Center Drive, Bethesda, MD 20892 1201, USA
    Nat Rev Clin Oncol 8:577-85. 2011
    Cancer immunotherapy using the adoptive transfer of autologous tumor-infiltrating lymphocytes results in objective cancer regression in 49-72% of patients with metastatic melanoma...
  54. pmc T-cell tolerance and the multi-functional role of IL-2R signaling in T-regulatory cells
    Guoyan Cheng
    Department of Microbiology and Immunology, Miller School of Medicine, University of Miami, Miami, FL 33136, USA
    Immunol Rev 241:63-76. 2011
    ..features of IL-2R signaling provide a mechanistic underpinning for using IL-2 as an agent to selectively target Treg cells in immunotherapy to induce tolerance in autoimmune diseases and in allogeneic transplant recipients.
  55. ncbi Mesothelin: a new target for immunotherapy
    Raffit Hassan
    Laboratory of Molecular Biology, National Cancer Institute, NIH, Bethesda, Maryland, USA
    Clin Cancer Res 10:3937-42. 2004
    ..There is evidence that mesothelin is an immunogenic protein and could be exploited as a therapeutic cancer vaccine. A soluble mesothelin variant has been identified and could be a useful tumor marker for malignant mesotheliomas...
  56. pmc Anti-TNF immunotherapy reduces CD8+ T cell-mediated antimicrobial activity against Mycobacterium tuberculosis in humans
    Heiko Bruns
    Institute for Medical Microbiology and Hygiene, University Hospital of Ulm, Germany
    J Clin Invest 119:1167-77. 2009
    ..tuberculosis, providing insight into the mechanism whereby key effector T cell subsets contribute to host defense against tuberculosis...
  57. pmc Antibody-mediated immunotherapy of macaques chronically infected with SHIV suppresses viraemia
    Masashi Shingai
    1 Laboratory of Molecular Microbiology, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland 20892, USA 2
    Nature 503:277-80. 2013
    ..These results indicate that immunotherapy or a combination of immunotherapy plus conventional antiretroviral drugs might be useful as a treatment for ..
  58. ncbi Awaiting a new era of cancer immunotherapy
    Cheng William Hong
    Cleveland Clinic Lerner College of Medicine, Cleveland, Ohio, USA
    Cancer Res 72:3715-9. 2012
    ..This line of research has the potential to vastly expand the field of antibody therapy and usher in a new era of cancer vaccines...
  59. pmc Radiation modulates the peptide repertoire, enhances MHC class I expression, and induces successful antitumor immunotherapy
    Eric A Reits
    Division of Tumor Biology, The Netherlands Cancer Institute, 1066 CX, Amsterdam, The Netherlands
    J Exp Med 203:1259-71. 2006
    ..We show that immunotherapy is successful in eradicating a murine colon adenocarcinoma only when preceded by radiotherapy of the tumor ..
  60. pmc Immunotherapy for ovarian cancer: what's next?
    Lana E Kandalaft
    Ovarian Cancer Research Center, University of Pennsylvania, Philadelphia, PA, USA
    J Clin Oncol 29:925-33. 2011
    ..With compelling evidence that ovarian cancers are immunogenic tumors, immunotherapy should be further pursued and optimized...
  61. pmc Sequential immunotherapy by vaccination with GM-CSF-expressing glioma cells and CTLA-4 blockade effectively treats established murine intracranial tumors
    Pankaj Agarwalla
    Department of Neurosurgery, Massachusetts General Hospital, Boston, MA 02114, USA
    J Immunother 35:385-9. 2012
    ..Several clinical trials have demonstrated that immunotherapy with vaccination is a safe and possibly effective way of prolonging survival...
  62. pmc Natural selection of tumor variants in the generation of "tumor escape" phenotypes
    Hung T Khong
    National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, USA
    Nat Immunol 3:999-1005. 2002
    ..Tumor escape variants are likely to emerge after treatment with increasingly effective immunotherapies...
  63. ncbi Prospects for the use of NK cells in immunotherapy of human cancer
    Hans Gustaf Ljunggren
    Centre for Infectious Medicine, Department of Medicine, Karolinska Institute, Karolinska University Hospital Huddinge, 141 86 Stockholm, Sweden
    Nat Rev Immunol 7:329-39. 2007
    ..Appropriately used, we predict that NK cells will have a role, both directly and in combination with other treatment modalities, in future treatment of cancer...
  64. ncbi Toll-like receptor expression and function in human dendritic cell subsets: implications for dendritic cell-based anti-cancer immunotherapy
    Gerty Schreibelt
    Department of Tumor Immunology, Nijmegen Centre for Molecular Life Sciences, Radboud University Nijmegen Medical Centre, PO Box 9101, 6500 HB, Nijmegen, The Netherlands
    Cancer Immunol Immunother 59:1573-82. 2010
    Dendritic cells (DCs) are central players of the immune response. To date, DC-based immunotherapy is explored worldwide in clinical vaccination trials with cancer patients, predominantly with ex vivo-cultured monocyte-derived DCs (moDCs)...
  65. pmc Chemokine nitration prevents intratumoral infiltration of antigen-specific T cells
    Barbara Molon
    Istituto Oncologico Veneto, Istituti di Ricovero e Cura a Carattere Scientifico IRCCS Venetian Oncological Institute, 35128 Padua, Italy
    J Exp Med 208:1949-62. 2011
    ..modification facilitates CTL invasion of the tumor, suggesting that these drugs may be effective in cancer immunotherapy. Our results unveil an unexpected mechanism of tumor evasion and introduce new avenues for cancer immunotherapy...
  66. ncbi Cancer immunotherapy--revisited
    W Joost Lesterhuis
    Department of Medical Oncology, Radboud University Nijmegen Medical Centre, P O Box 9101, 6500HB Nijmegen, The Netherlands
    Nat Rev Drug Discov 10:591-600. 2011
    ..into antitumour immune responses has increased considerably during the past decades, yet the development of immunotherapy as a treatment modality for cancer has been hampered by several factors...
  67. pmc A foundation for universal T-cell based immunotherapy: T cells engineered to express a CD19-specific chimeric-antigen-receptor and eliminate expression of endogenous TCR
    Hiroki Torikai
    Division of Pediatrics, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA
    Blood 119:5697-705. 2012
    ..CAR(+)TCR(neg) T cells of this type may potentially have efficacy as an off-the-shelf therapy for investigational treatment of B-lineage malignancies...
  68. pmc CTLA4 blockade and GM-CSF combination immunotherapy alters the intratumor balance of effector and regulatory T cells
    Sergio A Quezada
    Howard Hughes Medical Institute, Department of Immunology, Memorial Sloan Kettering Cancer Center, New York, New York, USA
    J Clin Invest 116:1935-45. 2006
    ..and CD8+ T cell activity within the tumor, highlight the importance of the intratumor ratio of effectors to regulators, and demonstrate inversion of the ratio and correlation with tumor rejection during Gvax/anti-CTLA4 immunotherapy.
  69. ncbi The next challenge in cancer immunotherapy: controlling T-cell traffic to the tumor
    Jean Pierre Abastado
    Singapore Immunology Network, Biomedical Sciences Institutes, A STAR, Singapore
    Cancer Res 72:2159-61. 2012
    One of the steps that limits the efficacy of T-cell-based immunotherapy of cancer is T-cell access to the tumor...
  70. pmc Acute myeloid leukemia stem cells and CD33-targeted immunotherapy
    Roland B Walter
    Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA 98109, USA
    Blood 119:6198-208. 2012
    ..Herein, we review studies on the nature of stem cells in AML, discuss clinical data on the effectiveness of CD33-directed therapy, and consider the mechanistic basis for success and failure in various AML subsets...
  71. pmc In vivo MRI cell tracking: clinical studies
    Jeff W M Bulte
    Russell H Morgan Department of Radiology, Division of MR Research, Institute for Cell Engineering, The Johns Hopkins University School of Medicine, Baltimore, MD 21205, USA
    AJR Am J Roentgenol 193:314-25. 2009
    ..The purpose of this review is to describe the principles of MRI cell tracking with superparamagnetic iron oxides and the four clinical trials that have been performed...
  72. pmc Redirecting T-cell specificity by introducing a tumor-specific chimeric antigen receptor
    Bipulendu Jena
    Division of Pediatrics, University of Texas M D Anderson Cancer Center, Houston, TX, USA
    Blood 116:1035-44. 2010
    ..To broaden the clinical application of adoptive immunotherapy against malignancies, investigators have developed robust systems for the genetic modification and ..
  73. pmc Structure and function analysis of therapeutic monoclonal antibodies against dengue virus type 2
    Soila Sukupolvi-Petty
    Department of Medicine, Washington University School of Medicine, 660 South Euclid Ave, Box 8051, St Louis, MO 63110, USA
    J Virol 84:9227-39. 2010
    ..Overall, these studies define the structural and functional complexity of antibodies against DENV-2 with protective potential...
  74. pmc Novel targeted immunotherapy approaches for staphylococcal infection
    Michael Otto
    National Institute of Allergy and Infectious Diseases, The National Institutes of Health, Laboratory of Human Bacterial Pathogenesis, 9000 Rockville Pike, Bethesda, MD 20892, USA
    Expert Opin Biol Ther 10:1049-59. 2010
    ..aureus infections often very complicated. In contrast to many other bacterial pathogens, a working vaccine has never been found for S. aureus despite considerable efforts in academia and pharmaceutical companies...
  75. pmc Immunotherapy earns its spot in the ranks of cancer therapy
    Drew Pardoll
    Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine, Baltimore, MD 21231, USA
    J Exp Med 209:201-9. 2012
    ..Although tumor-targeted antibodies have certainly cleared this bar, immunotherapies aimed at harnessing antitumor cellular responses have not-until now...
  76. ncbi Combined immunotherapy with granulocyte-macrophage colony-stimulating factor-transduced allogeneic prostate cancer cells and ipilimumab in patients with metastatic castration-resistant prostate cancer: a phase 1 dose-escalation trial
    Alfons J M van den Eertwegh
    Department of Medical Oncology, VU University Medical Centre, Amsterdam, Netherlands
    Lancet Oncol 13:509-17. 2012
    ..We aimed to assess the safety of combined treatment with GVAX and ipilimumab in patients with metastatic castration-resistant prostate cancer (mCRPC)...
  77. pmc Immunotherapy for Alzheimer's disease
    D Morgan
    Alzheimer s Institute, University of South Florida, Tampa, FL 33613, USA
    J Intern Med 269:54-63. 2011
    ..This was followed closely by demonstrations that vaccines or passive immunotherapy could rescue memory deficits in these mice...
  78. ncbi Potentiating endogenous antitumor immunity to prostate cancer through combination immunotherapy with CTLA4 blockade and GM-CSF
    Lawrence Fong
    Division of Hematology Oncology, University of California, San Francisco, San Francisco, California 94143, USA
    Cancer Res 69:609-15. 2009
    ..These results show that this combination immunotherapy can induce the expansion not only of activated effector CD8 T cells in vivo but also of T cells that are ..
  79. ncbi Gene signature in melanoma associated with clinical activity: a potential clue to unlock cancer immunotherapy
    Thomas F Gajewski
    University of Chicago, 5841 S Maryland Ave, MC2115, Chicago, IL 60637, USA
    Cancer J 16:399-403. 2010
    ..that such profiling might be useful as a predictive biomarker for clinical benefit from vaccines and other immunotherapy approaches, and analysis of specific gene products has begun to suggest new therapeutic interventions to ..
  80. pmc Arginase I-producing myeloid-derived suppressor cells in renal cell carcinoma are a subpopulation of activated granulocytes
    Paulo C Rodriguez
    Department of Microbiology, Stanley S Scott Cancer Center, Louisiana State University Health Sciences Center, New Orleans, Louisiana 70112, USA
    Cancer Res 69:1553-60. 2009
    ..These results may provide new insights on the mechanisms of tumor-induced anergy/tolerance and may help explain why some immunotherapies fail to induce an antitumor response...
  81. pmc Vaccination with dendritic cell/tumor fusion cells results in cellular and humoral antitumor immune responses in patients with multiple myeloma
    Jacalyn Rosenblatt
    Beth Israel Deaconess Medical Center, Boston, MA, USA
    Blood 117:393-402. 2011
    ..Vaccination with DC/multiple myeloma fusions was feasible and well tolerated and resulted in antitumor immune responses and disease stabilization in a majority of patients...
  82. pmc Frequent high-level expression of the immunotherapeutic target Ep-CAM in colon, stomach, prostate and lung cancers
    P Went
    Institute of Pathology, University Hospital Basel, Schonbeinstrasse 40, 4003 Basel, Switzerland
    Br J Cancer 94:128-35. 2006
  83. ncbi New aspects of natural-killer-cell surveillance and therapy of cancer
    Mark J Smyth
    Cancer Immunology Laboratory, Trescowthick Research Laboratories, Research Division, Peter MacCallum Cancer Institute, Locked Bag 1, A Beckett Street, Melbourne 8006, Australia
    Nat Rev Cancer 2:850-61. 2002
  84. ncbi Adoptive immunotherapy to lower postsurgical recurrence rates of hepatocellular carcinoma: a randomised trial
    T Takayama
    Department of Surgery, National Cancer Centre Research Institute, University of Tokyo, Japan
    Lancet 356:802-7. 2000
    Postsurgical recurrence of hepatocellular carcinoma (HCC) is frequent and fatal. Adoptive immunotherapy is active against HCC. We assessed whether postoperative immunotherapy could lower the frequency of recurrence.
  85. pmc Optimizing immunotherapy in multiple myeloma: Restoring the function of patients' monocyte-derived dendritic cells by inhibiting p38 or activating MEK/ERK MAPK and neutralizing interleukin-6 in progenitor cells
    Siqing Wang
    Department of Lymphoma and Myeloma, Center for Cancer Immunology Research, University of Texas M D Anderson Cancer Center, Houston, TX 77030, USA
    Blood 108:4071-7. 2006
    ..However, the phenotype and function of patients' monocyte-derived DCs (MoDCs), which are commonly used for immunotherapy, were poorly defined...
  86. pmc Involvement of PD-L1 on tumor cells in the escape from host immune system and tumor immunotherapy by PD-L1 blockade
    Yoshiko Iwai
    Department of Medical Chemistry, Graduate School of Medicine, Japan Science and Technology Corporation, Kyoto 606 8501, Japan
    Proc Natl Acad Sci U S A 99:12293-7. 2002
    ..of PD-L1 can serve as a potent mechanism for potentially immunogenic tumors to escape from host immune responses and that blockade of interaction between PD-1 and PD-L may provide a promising strategy for specific tumor immunotherapy.
  87. ncbi IL-10 and TGF-beta cooperate in the regulatory T cell response to mucosal allergens in normal immunity and specific immunotherapy
    Marek Jutel
    Swiss Institute of Allergy and Asthma Research SIAF, Davos, Switzerland
    Eur J Immunol 33:1205-14. 2003
    ..immune responses to airborne allergens in the mucosa is still poorly understood, and the mechanism of specific immunotherapy (SIT) in normalizing the allergic response to such allergens is currently not clear...
  88. ncbi Longitudinal analysis and prognostic effect of cancer-testis antigen expression in multiple myeloma
    Djordje Atanackovic
    Department of Oncology Hematology, University Medical Center Hamburg Eppendorf, Hamburg, Germany
    Clin Cancer Res 15:1343-52. 2009
  89. pmc Virus-specific T cells engineered to coexpress tumor-specific receptors: persistence and antitumor activity in individuals with neuroblastoma
    Martin A Pule
    Center for Cell and Gene Therapy, Baylor College of Medicine and The Methodist Hospital and Texas Children s Hospital, Houston, Texas 77030, USA
    Nat Med 14:1264-70. 2008
    ..Infusion of these genetically modified cells seemed safe and was associated with tumor regression or necrosis in half of the subjects tested. Hence, virus-specific CTLs can be modified to function as tumor-directed effector cells...
  90. pmc Gene expression profile correlates with T-cell infiltration and relative survival in glioblastoma patients vaccinated with dendritic cell immunotherapy
    Robert M Prins
    Department of Neurosurgery, Brain Research Institute, the Jonsson Comprehensive Cancer Center, University of California Los Angeles, Los Angeles, California 90095 6901, USA
    Clin Cancer Res 17:1603-15. 2011
    ..Clinical and immune responses were monitored and correlated with tumor gene expression profiles...
  91. pmc Tumor antigen-targeted, monoclonal antibody-based immunotherapy: clinical response, cellular immunity, and immunoescape
    Robert L Ferris
    The Hillman Cancer Center Research Pavilion, 5117 Centre Ave, Room 2 26b, Pittsburgh, PA 15213, USA
    J Clin Oncol 28:4390-9. 2010
    ..However, these results are only seen in a subset (20% to 30%) of patients. We discuss the immunologic mechanism(s) underlying these clinical findings and their potential role in the variability in patients' clinical response...
  92. pmc Novel cancer immunotherapy agents with survival benefit: recent successes and next steps
    Padmanee Sharma
    Department of Genitourinary Medical Oncology, University of Texas M D Anderson Cancer Center, Box 0018 7, 1515 Holcombe Boulevard, Houston, Texas 77030, USA
    Nat Rev Cancer 11:805-12. 2011
    The US Food and Drug Administration (FDA) recently approved two novel immunotherapy agents, sipuleucel-T and ipilimumab, which showed a survival benefit for patients with metastatic prostate cancer and melanoma, respectively...
  93. pmc Cancer testis antigens in newly diagnosed and relapse multiple myeloma: prognostic markers and potential targets for immunotherapy
    Mark van Duin
    Department of Hematology, Erasmus Medical Center Rotterdam, Rotterdam, The Netherlands
    Haematologica 96:1662-9. 2011
    ..myeloma, expression of cancer testis antigens may provide prognostic markers and potential targets for immunotherapy. Expression at relapse has not yet been evaluated for a large panel of cancer testis antigens which can be ..
  94. ncbi Regulatory T cells in melanoma: the final hurdle towards effective immunotherapy?
    Joannes F M Jacobs
    Department of Tumour Immunology, Nijmegen Centre for Molecular Life Sciences, Nijmegen, Netherlands
    Lancet Oncol 13:e32-42. 2012
    b>Immunotherapy studies in patients with melanoma have reported success in the expansion of tumour-specific effector T cells in vivo, but even in the presence of substantial numbers of functional T cells circulating in the blood, ..
  95. ncbi Long-term clinical efficacy of grass-pollen immunotherapy
    S R Durham
    Department of Upper Respiratory Medicine, Imperial College School of Medicine at the National Heart and Lung Institute, London, United Kingdom
    N Engl J Med 341:468-75. 1999
    Pollen immunotherapy is effective in selected patients with IgE-mediated seasonal allergic rhinitis, although it is questionable whether there is long-term benefit after the discontinuation of treatment.
  96. ncbi Mastocytosis and insect venom allergy: diagnosis, safety and efficacy of venom immunotherapy
    M Niedoszytko
    Department of Allergology, Medical University of Gdansk, Poland
    Allergy 64:1237-45. 2009 is to analyse the available data concerning prevalence, diagnosis, safety and effectiveness of venom immunotherapy (VIT) in mastocytosis patients...
  97. ncbi Recent advances in immunotherapy for the treatment of prostate cancer
    Guru Sonpavde
    Texas Oncology, Houston, Texas, USA
    Expert Opin Biol Ther 11:997-1009. 2011
    ..Prostate cancer vaccines attempt to induce cancer-specific systemic immune responses and represent a new class of targeted therapies, many of which are non-toxic. Several vaccine technologies are in development...
  98. pmc Prostate cancer immunotherapy
    Kenneth F May
    Department of Medical Oncology and Cancer Vaccine Center, Dana Farber Cancer Institute, Boston, MA 02215, USA
    Clin Cancer Res 17:5233-8. 2011
    ..In the context of prostate cancer, the immunotherapy strategies that have garnered the most interest are the therapeutic vaccination strategies, exemplified by ..
  99. pmc Ovarian cancer immunotherapy: opportunities, progresses and challenges
    Bei Liu
    Department of Immunology, University of Connecticut School of Medicine, Farmington, USA
    J Hematol Oncol 3:7. 2010
    ..Finally, we will summarize our own experience on the use of patient-specific tumor-derived heat shock protein-peptide complex for the treatment of advanced ovarian cancer...
  100. ncbi Phase 1/2 dose-escalation study of a GM-CSF-secreting, allogeneic, cellular immunotherapy for metastatic hormone-refractory prostate cancer
    Celestia S Higano
    Department of Oncology, University of Washington Seattle, Seattle, Washington, USA
    Cancer 113:975-84. 2008
    This open-label, multicenter, dose-escalation study evaluated multiple dose levels of immunotherapy in patients with metastatic hormone-refractory prostate cancer (HRPC)...
  101. ncbi Immunotherapy of myositis: issues, concerns and future prospects
    Marinos C Dalakas
    Imperial College London, Burlington Danes Building, Hammersmith Hospital Campus, Office E517, Du Cane Road, London W12 0NN, UK
    Nat Rev Rheumatol 6:129-37. 2010
    ..Novel agents are emerging as potential treatment options for all forms of myositis. This Review highlights common pitfalls in therapy, discusses emerging new therapies, and provides a practical therapeutic algorithm...

Research Grants77

  1. Personalized Clinical Diagnostics and Beyond: Integrated Ring Resonator Arrays
    Ryan Bailey; Fiscal Year: 2009
    ..This technology promises to broadly impact the landscape of the biomedical sciences, both meeting the clinical diagnostic challenges of today and pioneering the paradigm-shifting discoveries of tomorrow. ..
  2. Metabolic Engineering of Bacteria for Cancer Immunotherapy by Gamma Delta T Cells
    Craig T Morita; Fiscal Year: 2013
    ..since CD4 and CD8 12 T cells recognize these peptides bound to MHC molecules in an MHC-restricted fashion, immunotherapy with 12 T cells needs to be individualized for each MHC haplotype...
  3. Cellular &Inflammatory Pathways in Ashtma &Allergic Diseases: From IgE to Cells
    LAWRENCE BARRY SCHWARTZ; Fiscal Year: 2012
    ..Clinical tolerance due to desensitization can be distinguished from that due to immunotherapy by its rapid induction (hours) and short persistence (days) once allergen administration ceases...
  4. Statin modulation of immunotherapy for Alzheimer disease
    Jun Tan; Fiscal Year: 2012
    DESCRIPTION (provided by applicant): Statin modulation of immunotherapy for Alzheimer disease Summary/Abstract Alzheimer's disease (AD) is the most common dementing illness in the elderly and becoming major veteran's health ..
  5. Transgenesis and Xenotransplantation
    Jorge A Piedrahita; Fiscal Year: 2013
    ..They can be used to study adoptive immunotherapy, normal and abnormal immune system development and function, study development and treatment for diseases such ..
  6. Bi-functional Therapeutics for Allergy-BFTA
    Swey Shen Chen; Fiscal Year: 2010
    ..treatment targeting directly at IgE- mediated immune response: Allergen desensitization or specific immunotherapy (SIT) and anti-IgE passive antibody treatment or Xolair...
  7. Targeting iNOS to inhibit myeloid-derived suppressor cells (MDSC) in melanoma
    ANDREW GREGORY SIKORA; Fiscal Year: 2013
    ..patients, which play an increasingly recognized role in cancer maintenance, progression, and resistance to immunotherapy. MDSC infiltrate solid tumors, including coetaneous melanoma, and potently inhibit anti-tumor T cell responses ..
  8. Antibody-mediated Gene Therapy for the Treatment of Cancer
    TRACY RUTH DANIELS-WELLS; Fiscal Year: 2013
    ..TAA on the surface of cancer cells serve as excellent targets for immunotherapy. Therefore, the first level of my targeted strategy will occur through the use of a mouse/human chimeric ..
  9. Moffitt Skin Cancer SPORE
    Jeffrey S Weber; Fiscal Year: 2013
    ..PROJECTS AND CORES 12 PROJECT 1: Potentiating the Effects of Targeted and Cytotoxic Agents on Cell-Based Immunotherapy n Melanoma 12 PROJECT 2: Abrogation of Therapeutic Escape Pathways in BRAF Mutant Melanoma 16 PROJECT 3: ..
  10. Optimization of adoptive immunotherapy with autologous CD20-specific T cells
    Brian Till; Fiscal Year: 2013
    DESCRIPTION (provided by applicant): Optimization of adoptive immunotherapy with autologous CD20-specific T cells Non-Hodgkin lymphoma is diagnosed in more than 70,000 Americans each year, and aggressive B-cell lymphomas comprise ..
  11. Lysosomal phospholipase A2 in autoimmune disease
    JAMES ALAN SHAYMAN; Fiscal Year: 2013
    ..Despite these advances there remains no unifying hypothesis and no new mechanism based, directed immunotherapy for this disease...
  12. DNA Methylation Control Hematopoietic Stem Cell Lineage Differentiation
    GRANT ANTHONY CHALLEN; Fiscal Year: 2013
    ..these Centers includes hematopoiesis, stem cell biology, hemopoietic stem cell transplantation, gene therapy, immunotherapy, and vector development and provides ample opportnity for collaboration to further my scienific training...
  13. Gold Nanoparticle Assisted Delivery of Cancer Vaccines and Immune Stimulants
    Adam Lin; Fiscal Year: 2013
    ..In aim 3, CpG, a known inflammatory stimulant used for cancer immunotherapy, on AuNPs will be combined with AuNVs for a complete vaccine regimen...
  14. HIFU-enhanced tumor vaccines
    Chandan Guha; Fiscal Year: 2012
    ..The goal of this proposal is to build on the HIFU treatment of local tumors and combine HIFU with tumor immunotherapy to address metastatic cancer...
    Gregory J Zipfel; Fiscal Year: 2013
    ..assessment of cerebral arteriole function in transgenic mice producing endogenous A[unreadable] species;c) immunotherapy with anti-A[unreadable] antibodies that bind A[unreadable]40, A[unreadable]42, A[unreadable] oligomers, and/or ..
  16. Inflammation and Immunosuppression in Lung Cancer
    Cong Yan; Fiscal Year: 2013
    ..Accomplishment of the proposed studies will elucidate the molecular mechanism by which the LAL/hormonal ligands/PPAR? axis controls anti-tumor adaptive immunity and pave the way for novel immunotherapy of lung cancer.
  17. Autoimmunity Against Novel Antigens in Neuropsychiatric Dysfunction
    Josep O Dalmau; Fiscal Year: 2013
    ..the disorders affect young adults, including men and children with or without tumors;2) they are responsive to immunotherapy;3) some antibodies define new syndromes;4) the characterization of the antigens has resulted in unambiguous ..
  18. New Peptides for the Treatment of Multiple Sclerosis
    Christine Beeton; Fiscal Year: 2013
    ..Extensive in vitro and in vivo efficacy and safety studies have validated Kv1.3 as a target for immunotherapy and shown that the peptide ShK, originally isolated from a sea anemone, is not only a potent blocker of this ..
  19. Immunomodulation in melanoma therapy
    NOAH A CRAFT; Fiscal Year: 2012
    ..the effects of TLR7/8 on mouse and human DCs in vitro and optimize a combinatorial approach to melanoma immunotherapy using both DCs and rLM vaccines...
  20. Host defense against poxviruses and viral immune evasion
    Liang Deng; Fiscal Year: 2011
    ..have an important positive impact on the preventive and therapeutic interventions for poxvirus infection, and the design of safe and effective smallpox vaccines and poxvirus-based immunotherapy and oncolytic therapy.
    Hans Schreiber; Fiscal Year: 2013
    The objective is to examine Tn-O-glycopeptide antigens as targets for immunotherapy in a range of human cancers. A large percentage of common human cancers (e.g...
  22. Mechanisms of Peripheral Induction of T-Cell Tolerance
    ..cell enrichment can be used as a tool for early diagnosis of diabetes or to monitor the efficacy of immunotherapy. RELEVANCE: This project focuses on the mechanisms of immune tolerance that prevent CD4+ T cells from causing ..
  23. Suppression of Collagen Induced Arthritis with Altered Peptide Ligands
    Andrew H Kang; Fiscal Year: 2010
    ..We have used the animal model of CIA to develop a specific immunotherapy capable of selectively blocking autoimmunity without interfering with the beneficial functions of the immune ..
  24. Listeria-Based Therapeutic Cancer Vaccine for Melanoma
    Dirk G Brockstedt; Fiscal Year: 2011
    ..advances in the field of bacterial-based vaccine vectors have shown promising results for cancer-targeted immunotherapy. One such example is the use of live-attenuated and killed strains of the intracellular bacterium Listeria ..
  25. Vaccine Immunotoxin and Radioimmunotherapy of Primary and Metastatic CNS Tumors
    Darell D Bigner; Fiscal Year: 2013
    ..Targeted immunotherapy with monoclonal antibodies (MAbs) or their fragments armed with Astatine 211 or Pseudomonas exotoxin for the ..
  26. Hepatitis C: Studies of Immunity and Pathogenesis
    Charles Rice; Fiscal Year: 2009
    ..of conserved neutralization determinants that can be integrated into strategies for vaccination or passive immunotherapy. In addition, this panel of recombinant HCVcc expressing convenient reporters will facilitate screening ..
  27. Brain tumors with regulatory T-cells treated with EGFRvIII-specific T-cells
    John H Sampson; Fiscal Year: 2013
    ..In contrast, immunotherapy promises an exquisitely precise approach, and substantial evidence suggests that T-cells can eradicate large, ..
  28. Biobehavioral Role of Brain Kynurenine Metabolism in Mental Illness
    JASON C O'CONNOR; Fiscal Year: 2013
    ..Patients receiving cytokine immunotherapy for treatment of viral infections or malignancies and those suffering from chronic inflammatory diseases are ..
  29. Vaccines to promote Tc-1-based targeting of tumor stroma
    Walter J Storkus; Fiscal Year: 2013 (Specific Aim 1), and that co-therapies integrating such vaccines will improve the (co)delivery of chemo/immunotherapy agents into the TME, yielding enhanced therapy benefit via a broadening in the therapeutic T cell repertoire (..
  30. Pathogensis of Bacterial corneal infection
    Gerald B Pier; Fiscal Year: 2013
    ..will be evaluated in the murine model of corneal injury to determine if PNAG is a rationale target for immunotherapy of S. aureus corneal infection...
  31. Tissue compartmentalization of human lymphocytes
    Donna L Farber; Fiscal Year: 2013 human immunology and impact the way we analyze and interpret disease pathologies, design vaccines, and use immunotherapy to treat and cure intractable diseases...
  32. Use of Allogenicity to Stimulate Effector Responses Against Multiple Myeloma
    Christina N Johnson; Fiscal Year: 2013
    ..b>Immunotherapy strategies have also been developed...
  33. The role of plasmacytoid dendritic cells in corneal immunity
    Pedram Hamrah; Fiscal Year: 2013
    ..and T cell migration in the cornea may provide new molecular targets for pharmacological intervention through immunotherapy. However, defining organ- and cell-specific molecular migratory mechanisms is critical, in order to inhibit ..
  34. Analyzing the Efficacy of Galectin-1 Ligand Inhibition in Adoptive T cell Therapy
    JENNA GEDDES SWEENEY; Fiscal Year: 2012
    ..Thus, blocking Gal-1-Gal-1 ligand interactions on antigen-specific CTLs, prior to adoptive immunotherapy, could help avoid current shortcomings, such as T cell susceptibility to tumor-derived Gal-1, thereby ..
  35. Improved idiotype immunotherapy for lymphoma by RNA vaccine delivery
    ALISON ANNE MCCORMICK; Fiscal Year: 2010
    ..Unlike current therapies, custom vaccines are easily made, and may facilitate widespread adoption of individualized patient immunotherapy.
    Olivia M Martinez; Fiscal Year: 2012
    ..such as anti-viral drugs, B cell specific antibodies including anti-CD20 (Rituximab) and adoptive cellular immunotherapy. However, each of these approaches has distinct limitations...
  37. Phase 1 Study of Umbilical Cord Blood-Derived T Cells in Malignant B Cells
    Elizabeth J Shpall; Fiscal Year: 2013
    ..This proposal seeks to apply this adoptive immunotherapy to prevent relapse after allogeneic umbilical cord blood transplantation in the setting of a first-in-human ..
  38. Immunosuppression by Adult Stem Cells
    Yufang Shi; Fiscal Year: 2013
    ..of the mechanisms underlying these effects will lead to better clinical protocols for immune disorders, cancer immunotherapy and vaccine design...
  39. SPORE in Skin Cancer
    Meenhard Herlyn; Fiscal Year: 2009 therapeutic efficacy can be enhanced by cytokines, including IL-2 (Project 5);and c) active and passive immunotherapy of melanoma with lymphocytes and defined tumor antigens: an organotypic model of melanoma will define new ..
  40. Development of Cross Protective H5 Hemagglutinin Antigens
    Susan C Bock; Fiscal Year: 2010
    ..we develop may be useful as "universal" immunogens and provide broad H5 protection in vaccination and immunotherapy protocols. Specific Aim 1 is to design, express and purify milligram amounts of several hemagglutinins...
  41. Enterovirus Vectors with Respiratory Tropism for Cancer Immunotherapy
    Matthias Gromeier; Fiscal Year: 2010
    ..b>Immunotherapy approaches target glioma cells directly, via antigenic signatures unique to tumor, or indirectly by attacking ..
  42. Modulation of T cell Homeostasis in Myelodysplastic Syndrome (MDS)
    Javier Pinilla; Fiscal Year: 2012
    ..Mechanistic studies will aide our understanding of T-cell immunity and improve our ability to utilize this form of immunotherapy and other forms for the treatment of cancer in general.
  43. CD8+ T Cell Immunity to Cytomegalovirus
    Stanley R Riddell; Fiscal Year: 2013
    ..project have investigated the immunobiology of CMV infection and developed strategies for specific adoptive immunotherapy with CD8+ T cell clones to correct deficiencies of T cell immunity that permit the progression of CMV ..
  44. Glioma immunotherapy with strategies based on autonomous parvovirus MVMp
    JUSTIN COBB PAGLINO; Fiscal Year: 2013
    ..Although I have knowledge of immunobiology and cancer immunotherapy, I seek to understand it on a level that will allow me to make needed advances in this field...
  45. In Vivo Imaging of bcl-2 Expression in Lymphoma
    Michael R Lewis; Fiscal Year: 2012
    ..Bcl-2-positive patients might respond better to alternative treatments, such as targeted immunotherapy, radioimmunotherapy (RIT), or antisense therapy, all of which act through mechanisms that down-regulate bcl- 2...
  46. SPORE in Lymphoma
    Richard Ambinder; Fiscal Year: 2009
    ..decisions regarding the duration or intensity of therapy and to determine whether vaccination and/or adoptive immunotherapy strategies may ultimately allow standard therapies to be shortened or de-escalated in some patients...
  47. Humanization of a mouse anti-OX40 monoclonal antibody to treat cancer
    Andrew D Weinberg; Fiscal Year: 2012
    ..provided by applicant): Current cancer management options include chemotherapy, radiation therapy, surgery, immunotherapy, monoclonal antibody therapy and other experimental treatments...
  48. The Three Rs of Immunity: Recognition, Response and Resolution
    Robert A Clark; Fiscal Year: 2010
    ..further our understanding of the unique relationships among leukocytes, mechanisms of disease, and advances in immunotherapy. The specific objectives of the conference are as follows: Objective 1...
  49. Targeting MCPyV to Overcome Immune Evasion in Merkel Cell Carcinoma
    Paul Nghiem; Fiscal Year: 2010
    ..the immune evasion strategies adopted by MCC and begin the process of developing rational vaccine or adoptive immunotherapy for this disease...
  50. Improving the efficacy of anti-nicotine immunotherapy
    Alexey G Mukhin; Fiscal Year: 2010
    ..The long-term goal of this research project is to improve the efficacy of anti-nicotine vaccination/immunotherapy for smoking cessation...
  51. Novel IL-15 Superagonist Therapy for Bladder Cancer
    Hing C Wong; Fiscal Year: 2011
    ..NMIBC are usually treated by surgical resection and intravesical chemotherapy and immunotherapy. Immunotherapy usually consists of intravesical administration of Bacillus Calmette-Guerin (BCG), a live, ..
  52. cGMP manufacturing of PBI-220, a broad spectrum immunoadhesin therapeutic against
    LLOYD M YU; Fiscal Year: 2013
    ..We are developing PBI-220, using the Animal Rule, for passive immunotherapy to complement the use of Ciprofloxacin during treatment of this infection...
    Amy K Wesa; Fiscal Year: 2012 vivo following therapeutic cell transfer is one of the greatest bottlenecks in the development of cancer immunotherapy. A commonly cited reason for the highly varied clinical outcomes of current DC-based vaccines is sub-optimal ..
  54. IL-15 Superagonist Complex as an Immunotherapeutic for Multiple Myeloma
    Hing C Wong; Fiscal Year: 2012
    ..animal models and is listed by a recent NCI review as the most promising product candidate among twelve immunotherapy drugs that could potentially cure cancer...
  55. Imaging and Function of the Immunological Synapse
    David C Parker; Fiscal Year: 2012 a basic understanding of the regulation CD4 T cell effector functions, which in turn will have public health-related applications in transplantation, autoimmunity, allergy, cancer immunotherapy, and control of infectious diseases.
    REBECCA CYNTHIA OBENG; Fiscal Year: 2010
    ..This will therefore make phosphopeptides great candidates for immunotherapy and we wish to explore their use as immunotherapeutic agents for breast cancer patients...
  57. Engineered tumor-specific T cells Resist Hypoxic-Tumor Immunosuppressive Attacks.
    Patricia Yotnda; Fiscal Year: 2013
    ..ubiquitous hypoxia and reactive oxygen species in the tumor microenvironment that impede the success of tumor immunotherapy. Aggressive hypoxic tumors are radio- and chemo-resistant, and metastasize rapidly...
  58. Combination immunotherapy with gene modified CD4 and CD8 T cells and stem cells
    Carl H June; Fiscal Year: 2013
    ..Adaptimmune Ltd, we developed HIV gag specific TCRs, a strategy that has recently also shown promise in cancer immunotherapy (Varela et al, in press)...
  59. Immunotherapy against tauopathy in a transgenic mouse model
    David Morgan; Fiscal Year: 2013
    ..b>Immunotherapy is rapidly advancing with almost 30 FDA approved medications...
  60. GUCY2C targeted adoptive T cell therapy to treat metastatic colorectal cancer
    Michael S Magee; Fiscal Year: 2013
    ..and by derivative tumors, with unique characteristics which make them effective as targets in cancer immunotherapy. GUCY2C is selectively expressed in apical membranes of intestinal epithelial cells in the mucosal compartment,..
  61. Diagnostic Tests and Immunotherapy of Sarcoidosis Using Mycobacterial Proteins
    David R Moller; Fiscal Year: 2012
  62. Development & Characterization of Tyrosinase Epitope Specific TCR Transgenic Mice
    Shikhar Mehrotra; Fiscal Year: 2010
    ..complex molecules provide targets for vaccination-induced, cytotoxic T lymphocyte (CTL)-based immunotherapy of malignant melanoma...
  63. NKT Cells Immunotherapy: Targeting Dendritic Cells with Glycolipid Liposomes
    Peng Wang; Fiscal Year: 2007
    ..So far, a much more successful NKT cell immunotherapy approach is to re-induce human mature dendritic cells pulsed with alpha-GalCer ex vivo into patient to expand ..
  64. Clinical Trial of DRibble Vaccine in NSCLC
    Walter Urba; Fiscal Year: 2009
    ..b>Immunotherapy has produced tantalizing responses in a few NSCLC patients but has not been applicable widely...
  65. Mechanisms of oral immunotherapy-induced suppression of type I hypersensitivity.
    Wayne G Shreffler; Fiscal Year: 2009
    ..clinical trials will evaluate the effectiveness of gradually administering peanut allergen by mouth (oral immunotherapy or OIT) on protecting patients from allergic reactions and ultimately curing them of their allergy...
  66. ApoVax-SVN as a Novel Vaccine for Cancer Immunotherapy
    Haval Shirwan; Fiscal Year: 2007
    ..them for the generation of an effective anti-tumor immune response with therapeutic efficacy for cancer immunotherapy. Therapeutic vaccines represent an attractive treatment modality for the management of cancer, primarily due ..
  67. Statins for Alzheimer's disease immunotherapy
    Ken Ichiro Fukuchi; Fiscal Year: 2009
    ..Another obstacle for AD immunotherapy is the difficulty to induce an appropriate anti-Ab titer in AD patients. In the phase II clinical trial, 19...
  68. Monoclonal Antibodies Against T-Regulatory Cells
    Alan Epstein; Fiscal Year: 2005
    b>Immunotherapy is a powerful therapeutic modality that has great potential for the treatment of cancer...
  69. Immunomodulatory Mechanisms of Sublingual Immunotherapy
    Louis Rosenthal; Fiscal Year: 2006
    ..of asthma and allergic rhinitis associated with aeroallergen sensitization is allergen-specific subcutaneous immunotherapy (SCIT), which involves a series of subcutaneous injections of allergen extracts...
  70. Soy Immunotherapy for Patients with Peanut Anaphylaxis
    ARVIL BURKS; Fiscal Year: 2004
    ..Due to the persistence of this reaction and the lack of effective treatment, allergen-specific immunotherapy (IT) is currently being examined as a treatment option...
  71. Antigen Discovery and Development of Tumor-Specific Lymphoma Immunotherapy
    Sattva S Neelapu; Fiscal Year: 2010
    ..Dr. Neelapu is a physician scientist with laboratory training in cancer immunotherapy and clinical training in lymphoma medical oncology...
    John Levine; Fiscal Year: 2006
    ..Dr. Levine's long-term goal is to conduct clinical research in cellular immunotherapy for hematologic disorders. Dr...
  73. Cognitive Recovery and Neuronal Plasticity after Stroke in the Aged
    REBECCA LYNN GILLANI; Fiscal Year: 2010
    ..Our laboratory has shown that a novel treatment, anti-Nogo-A immunotherapy results in sensorimotor functional recovery after stroke in rodents...
  74. Cat allergen-human Fc-gamma1 chimeric proteins to treat cat allergy
    NOLAN contact SIGAL; Fiscal Year: 2010
    ..The overall goal of this SBIR proposal is to develop and commercialize a new approach for allergen specific immunotherapy as treatment for cat allergy...
  75. Immunotherapy for Peanut Allergy
    ARVIL BURKS; Fiscal Year: 2007
    ..Based on a novel idea that allergen-specific, sublingual immunotherapy (SLIT) would desensitize or tolerize allergic patients, we propose to utilize this alternative therapy in ..
    STANLEY LEONG; Fiscal Year: 2000
    ..pre-effector cells against autologous melanoma may be induced in the draining lymph nodes by active specific immunotherapy. However, these pre-effector cells may not be active unless they become activated in vitro to become effector ..
  77. Lentiviral Vectors for TCR Immunotherapy Targeted to melanoma
    Boro Dropulic; Fiscal Year: 2006
    ..epitope, a melanoma/melanocytes differentiation tumor associated antigen have improved efficacy for melanoma immunotherapy. According to the American Cancer Society melanoma is currently the 6th most common cancer in American men and ..